Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free HKMPF Stock Alerts

Hikma Pharmaceuticals (HKMPF) Short Interest Ratio & Short Volume

Hikma Pharmaceuticals logo
$22.28 0.00 (0.00%)
As of 08/10/2026
Compare

Hikma Pharmaceuticals Short Interest Overview

As of July 31, 2026, Hikma Pharmaceuticals (HKMPF) had a short interest of 137,438 shares sold short, representing 0.06% of the public float. This marks a -7.28% decrease in short interest since the prior report. The short interest ratio (days to cover) is 630.5, meaning it would take 630.5 days of the average trading volume of 75 shares to cover all short positions.

Current Short Interest
137,438 shares
Previous Short Interest
148,237 shares
Change Vs. Previous Month
-7.28%
Dollar Volume Sold Short
$2.96 million
Short Interest Ratio
630.5 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
221,886,000 shares
Short Percent of Float
0.06%
Today's Trading Volume
0 shares
Average Trading Volume
75 shares
Today's Volume Vs. Average
0%
Short Selling Hikma Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

HKMPF Short Interest Over Time

HKMPF Days to Cover Over Time

HKMPF Percentage of Float Shorted Over Time

Hikma Pharmaceuticals Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/2026137,438 shares $2.96 million -7.3%0.1%630.45 $21.56
7/15/2026148,237 shares $3.15 million +1.2%0.1%86.13 $21.26
6/30/2026146,504 shares $2.95 million -2.8%0.1%196.65 $20.12
6/15/2026150,741 shares $2.91 million +1.7%0.1%999.99 $19.29
5/29/2026148,300 shares $2.96 million -0.1%0.1%999.99 $19.95
5/15/2026148,384 shares $2.89 million -1.6%0.1%173.55 $19.50
4/30/2026150,785 shares $2.73 million -1.6%0.1%169.42 $18.10
4/15/2026153,152 shares $2.76 million -1.6%0.1%132.6 $18.00
3/31/2026155,703 shares $2.69 million -2.9%0.1%453.94 $17.30
3/13/2026160,336 shares $2.63 million +0.2%0.1%43.29 $16.40
2/27/2026160,005 shares $2.88 million +13.3%0.1%135.6 $18.00
2/13/2026141,243 shares $3.07 million +5.9%0.1%353.11 $21.76
1/30/2026133,381 shares $2.79 million -1.2%0.1%38.55 $20.92
1/15/2026134,951 shares $2.81 million +13.5%0.1%128.89 $20.79
12/31/2025118,916 shares $2.49 million +2.7%0.1%66.1 $20.94
12/15/2025115,841 shares $2.36 million -3.2%0.1%207.97 $20.40
11/28/2025119,680 shares $2.46 million +5.6%0.1%430.5 $20.55
11/14/2025425,320 shares $8.79 million +2.1%0.2%309.77 $20.67
10/31/2025416,443 shares $10.13 million +21.6%0.2%110.23 $24.32
10/15/2025342,400 shares $8.21 million +0.5%0.2%1141.3 $23.98
9/30/2025340,800 shares $7.65 million -3.8%N/A309.8 $22.46
9/15/2025354,300 shares $7.85 million +17.4%N/A75.4 $22.16
8/31/2025301,700 shares $7.39 million -3.2%0.1%502.8 $24.50
8/15/2025311,600 shares $7.47 million +1.8%N/A3116 $23.96
7/31/2025306,100 shares $8.07 million -4.6%0.1%1530.5 $26.38
7/15/2025320,900 shares $8.90 million +0.5%N/A3209 $27.73
6/30/2025319,400 shares $8.86 million -8.6%0.1%3194 $27.73
6/15/2025349,300 shares $9.69 million -46.2%0.2%873.3 $27.73
5/31/2025648,600 shares $17.99 million -3.4%0.3%6486 $27.73
5/15/2025671,400 shares $18.08 million -4.5%0.3%6714 $26.93
4/30/2025702,800 shares $18.41 million -1.0%N/A0 $26.20
4/15/2025709,600 shares $18.59 million -3.7%0.3%1419.2 $26.20
3/31/2025736,500 shares $19.29 million +4.4%0.3%2455 $26.20
3/15/2025705,400 shares $18.20 million +1.6%0.3%1007.7 $25.80
2/28/2025694,500 shares $18.87 million -6.7%0.3%330.7 $27.17
2/15/2025744,500 shares $20.95 million -32.5%0.3%7445 $28.14
1/31/20251,103,100 shares $29.39 million -3.2%N/A3677 $26.64
1/15/20251,139,700 shares $28.03 million +0.7%N/A1036.1 $24.59
12/31/20241,132,100 shares $27.31 million -26.1%N/A5660.5 $24.12
12/15/20241,531,300 shares $38.08 million +0.6%N/A1276.1 $24.87
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
11/30/20241,522,000 shares $37.24 million -0.3%N/A15220 $24.47
11/15/20241,526,800 shares $34.44 million +1.1%N/A15268 $22.56
10/31/20241,509,700 shares $37.85 million -2.9%N/A0 $25.07
10/15/20241,554,200 shares $39.10 million +0.7%N/A15542 $25.16
9/30/20241,544,100 shares $39.68 million -0.3%N/A15441 $25.70
9/15/20241,547,900 shares $39.78 million +0.4%N/A15479 $25.70
8/31/20241,541,500 shares $40.02 million -2.1%N/A2202.1 $25.96
8/15/20241,574,300 shares $41.04 million -17.0%N/A1211 $26.07
7/31/20241,896,300 shares $45.51 million +0.2%N/A3792.6 $24.00
7/15/20241,892,500 shares $44.86 million +0.1%N/A6308.3 $23.70
6/30/20241,891,200 shares $47.75 million +1.0%N/A18912 $25.25
6/15/20241,872,400 shares $47.28 million +0.5%N/A3744.8 $25.25
5/31/20241,862,300 shares $45.63 million -0.1%N/A18623 $24.50
5/15/20241,863,300 shares $45.65 million +0.7%N/A6211 $24.50
4/30/20241,849,700 shares $41.30 million +6.2%N/A9248.5 $22.33
4/15/20241,741,900 shares $42.24 million 0.0%N/A5806.3 $24.25
3/31/20241,742,100 shares $40.71 million +0.2%N/A8710.5 $23.37
3/15/20241,739,000 shares $40.64 million 0.0%N/A8695 $23.37
2/29/20241,739,100 shares $46.09 million +0.1%N/A5797 $26.50
2/15/20241,737,700 shares $43.44 million -1.2%N/A2172.1 $25.00
1/15/20241,756,000 shares $43.30 million No ChangeN/A8780 $24.66
12/31/20231,756,000 shares $40.01 million -10.0%N/A2676.8 $22.79
12/15/20231,951,100 shares $43.02 million +0.1%N/A19511 $22.05
11/30/20231,948,900 shares $42.95 million +0.3%N/A721.8 $22.04
11/15/20231,944,100 shares $43.28 million +0.5%N/A4860.3 $22.26
10/31/20231,934,300 shares $45.24 million +4.5%N/A4835.8 $23.39
10/15/20231,850,400 shares $46.97 million +5.5%N/A9252 $25.38
9/30/20231,754,100 shares $47.36 million -1.1%N/A17541 $27.00
9/15/20231,774,300 shares $47.91 million -0.1%N/A17743 $27.00
8/31/20231,775,300 shares $47.93 million +0.1%N/A1894.6 $27.00
8/15/20231,774,500 shares $46.94 million +0.1%N/A4436.3 $26.45
7/31/20231,773,300 shares $46.90 million +13.1%N/A479.3 $26.45
7/15/20231,567,500 shares $36.24 million 0.0%N/A1045 $23.12
6/30/20231,567,700 shares $36.21 million -8.0%N/A7838.5 $23.10
6/15/20231,703,900 shares $40.89 million +0.4%N/A8519.5 $24.00
5/31/20231,697,100 shares $39.03 million -0.3%N/A5657 $23.00
5/15/20231,702,000 shares $38.96 million -0.7%N/A17020 $22.89
4/30/20231,714,200 shares $39.72 million +0.4%N/A2857 $23.17
4/15/20231,707,400 shares $35.24 million +11.9%N/A17074 $20.64
3/31/20231,526,500 shares $30.94 million -2.7%N/A1908.1 $20.27
3/15/20231,569,000 shares $32.38 million -0.2%N/A2241.4 $20.64
2/28/20231,571,400 shares $33.20 million +0.3%N/A3928.5 $21.13
2/15/20231,567,000 shares $32.67 million -0.9%N/A3134 $20.85
1/31/20231,580,400 shares $29.82 million +0.6%N/A0 $18.87
1/15/20231,571,500 shares $29.65 million -0.6%N/A0 $18.87
12/30/20221,581,500 shares $29.84 million +0.0%N/A3953.8 $18.87
12/15/20221,581,200 shares $29.84 million -0.1%N/A15812 $18.87
11/30/20221,582,800 shares $22.62 million -0.3%N/A3165.6 $14.29
11/15/20221,588,000 shares $22.69 million +0.3%N/A15880 $14.29
10/31/20221,582,900 shares $22.62 million +0.2%N/A3165.8 $14.29
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
10/15/20221,579,400 shares $22.55 million +0.4%N/A493.6 $14.28
9/30/20221,572,800 shares $21.64 million +0.2%N/A1966 $13.76
9/15/20221,569,100 shares $23.32 million +114.5%N/A412.9 $14.86
8/31/2022731,700 shares $10.87 million No ChangeN/A385.1 $14.86
8/15/2022731,700 shares $14.20 million +0.5%N/A7317 $19.41
7/31/2022727,800 shares $14.62 million +0.5%N/A7278 $20.09
7/15/2022724,400 shares $14.22 million +54.8%N/A2414.7 $19.63
6/30/2022468,100 shares $8.51 million +0.3%N/A173.4 $18.19
6/15/2022466,700 shares $9.72 million +16.2%N/A4667 $20.82
5/31/2022401,700 shares $8.36 million +3,454.9%N/A0 $20.82
5/15/202211,300 shares $235.27 thousand -86.6%N/A4.7 $20.82
4/30/202284,600 shares $2.37 million -1.7%N/A282 $28.00
4/15/202286,100 shares $2.41 million -1.3%N/A861 $28.00
3/31/202287,200 shares $2.44 million +87.1%N/A79.3 $28.00
3/15/202246,600 shares $1.13 million +639.7%N/A66.6 $24.30
2/28/20226,300 shares $176.40 thousand -19.2%N/A21 $28.00
2/15/20227,800 shares $210.60 thousand -41.8%N/A78 $27.00
1/31/202213,400 shares $361.13 thousand -1.5%N/A33.5 $26.95
1/15/202213,600 shares $384.20 thousand -26.5%N/A34 $28.25
12/31/202118,500 shares $529.84 thousand -66.5%N/A46.3 $28.64
12/15/202155,200 shares $1.60 million +1,477.1%N/A276 $28.92
11/30/20213,500 shares $112 thousand +169.2%N/A35 $32.00
11/15/20211,300 shares $41.60 thousand +44.4%N/A13 $32.00
10/29/2021900 shares $28.80 thousand -35.7%N/A9 $32.00
10/15/20211,400 shares $44.80 thousand +7.7%N/A14 $32.00
9/30/20211,300 shares $44.53 thousand -23.5%N/A13 $34.25
9/15/20211,700 shares $58.31 thousand -97.8%N/A17 $34.30
8/31/202177,600 shares $2.66 million -72.7%N/A388 $34.30
8/13/2021284,000 shares $9.94 million -13.2%N/A946.7 $35.00

HKMPF Short Interest - Frequently Asked Questions

Short interest is the volume of Hikma Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 137,438 shares of HKMPF short. 0.06% of Hikma Pharmaceuticals' shares are currently sold short. Learn More on Hikma Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HKMPF shares currently have a short interest ratio of 630.5. Learn More on Hikma Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.06% of Hikma Pharmaceuticals' floating shares are currently sold short.

Hikma Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 137,438 shares, a decline of 7.3% from the previous total of 148,237 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.06% of Hikma Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Hikma Pharmaceuticals: Neurocrine Biosciences, Inc. (4.53%), IPSEN (0.00%), Jazz Pharmaceuticals PLC (5.39%), Shionogi & Co., Ltd. Unsponsored ADR (0.00%), Elanco Animal Health Incorporated (7.29%), Corcept Therapeutics Incorporated (11.46%), Orion OYJ Unsponsored ADR (0.00%), Recordati Industria Chimica E Farmaceutica S.P.A. (0.04%), Axsome Therapeutics, Inc. (8.34%), Dr. Reddy's Laboratories Ltd (2.55%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling HKMPF is an investing strategy that aims to generate trading profit from Hikma Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Hikma Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HKMPF, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HKMPF, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like HKMPF:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for OTCMKTS:HKMPF is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel